Physical Medicine and Rehabilitation for Iliotibial Band Syndrome Medication

Updated: Apr 27, 2020
  • Author: John M Martinez, MD; Chief Editor: Stephen Kishner, MD, MHA  more...
  • Print
Medication

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and prevent complications.

Next:

Nonsteroidal anti-inflammatory drugs

Class Summary

Have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase (COX) activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.

Ibuprofen (Advil, Motrin)

DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Naproxen (Naprelan, Naprosyn, Anaprox)

For relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which results in a decrease of prostaglandin synthesis.

Ketoprofen (Oruvail, Orudis, Actron)

For relief of mild to moderate pain and inflammation. Small dosages initially are indicated in small and elderly patients and in those with renal or liver disease.

Doses over 75 mg do not increase therapeutic effects. Administer high doses with caution, and closely observe patient for response.

Previous
Next:

Cyclooxygenase-2 Inhibitors

Class Summary

COX-2 inhibitors are a new class of NSAIDs that report a lower incidence of GI side effects, such as gastritis and ulcers. COX-2 inhibitors may be indicated in patients who require anti-inflammatory medications but who have a history of gastric ulcers.

Celecoxib (Celebrex)

For relief of mild to moderate pain. Primarily inhibits COX-2. COX-2 is considered an inducible isoenzyme, induced during pain and with inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID-related GI toxicity. At therapeutic concentrations, COX-1 isoenzyme is not inhibited, thus GI toxicity may be decreased. Seek lowest dose of celecoxib for each patient.

Previous